knowledge -WSS

knowledge

author：focus 2025-08-28 02:48:49 - browse：241

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Male doctors called my cancer incurable. A female doctor showed it wasn't

knowledge

WSS

The history of OxyContin, told through Purdue Pharma documents

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Merck to acquire Harpoon Therapeutics for $680 million

TB outbreak tied to bone grafts underscores testing shortcomings

Stories you might have missed in 2023: health, science, medicine

In shift, Texas to cover initial consult for Afghan baby's gene therapy

leisure time

knowledge

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After John Oliver segment, STAT readers share their opioid

How one medical school became remarkably diverse

TB outbreak tied to bone grafts underscores testing shortcomings

Affirmative action in medical school literally saved lives

Covid's long

Medicare proposal to cover medical devices draws a mixed reaction

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

How one medical school became remarkably diverse

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

Gene therapy denied for Afghan refugee whose father aided U.S.

Medicare Advantage overpayments discussion gets experts fired up

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

GOP presidential candidates start declaring their loyalty

The history of OxyContin, told through Purdue Pharma documents

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

knowledge

hotspot

entertainment